Literature DB >> 35606492

Enzymatically amplified linear dbDNATM as a rapid and scalable solution to industrial lentiviral vector manufacturing.

Maria Barreira1,2, Claire Kerridge1, Sara Jorda1,3, Didrik Olofsson4, Alexander Neumann4, Helen Horton1, Sarah Smith-Moore5.   

Abstract

Traditional bacterial fermentation techniques used to manufacture plasmid are time-consuming, expensive, and inherently unstable. The production of sufficient GMP grade material thus imposes a major bottleneck on industrial-scale manufacturing of lentiviral vectors (LVV). Touchlight's linear doggybone DNA (dbDNATM) is an enzymatically amplified DNA vector produced with exceptional speed through an in vitro dual enzyme process, enabling industrial-scale manufacturing of GMP material in a fraction of the time required for plasmid. We have previously shown that dbDNATM can be used to produce functional LVV; however, obtaining high LVV titres remained a challenge. Here, we aimed to demonstrate that dbDNATM could be optimised for the manufacture of high titre LVV. We found that dbDNATM displayed a unique transfection and expression profile in the context of LVV production, which necessitated the optimisation of DNA input and construct ratios. Furthermore, we demonstrate that efficient 3' end processing of viral genomic RNA (vgRNA) derived from linear dbDNATM transfer vectors required the addition of a strong 3' termination signal and downstream spacer sequence to enable efficient vgRNA packaging. Using these improved vector architectures along with optimised transfection conditions, we were able to produce a CAR19h28z LVV with equivalent infectious titres as achieved using plasmid, demonstrating that dbDNATM technology can provide a highly effective solution to the plasmid bottleneck.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 35606492     DOI: 10.1038/s41434-022-00343-4

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  34 in total

1.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

Review 2.  Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks.

Authors:  D M Prazeres; G N Ferreira; G A Monteiro; C L Cooney; J M Cabral
Journal:  Trends Biotechnol       Date:  1999-04       Impact factor: 19.536

3.  Self-inactivating lentiviral vectors with U3 and U5 modifications.

Authors:  T Iwakuma; Y Cui; L J Chang
Journal:  Virology       Date:  1999-08-15       Impact factor: 3.616

4.  A third-generation lentivirus vector with a conditional packaging system.

Authors:  T Dull; R Zufferey; M Kelly; R J Mandel; M Nguyen; D Trono; L Naldini
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

5.  Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells.

Authors:  S F Yu; T von Rüden; P W Kantoff; C Garber; M Seiberg; U Rüther; W F Anderson; E F Wagner; E Gilboa
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

6.  Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.

Authors:  R Zufferey; T Dull; R J Mandel; A Bukovsky; D Quiroz; L Naldini; D Trono
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

7.  CAR T Cell Generation by piggyBac Transposition from Linear Doggybone DNA Vectors Requires Transposon DNA-Flanking Regions.

Authors:  David C Bishop; Lisa Caproni; Kavitha Gowrishankar; Michal Legiewicz; Kinga Karbowniczek; John Tite; David J Gottlieb; Kenneth P Micklethwaite
Journal:  Mol Ther Methods Clin Dev       Date:  2020-01-16       Impact factor: 6.698

8.  Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model.

Authors:  Alex Allen; Chuan Wang; Lisa J Caproni; Gessa Sugiyarto; Elena Harden; Leon R Douglas; Patrick J Duriez; Kinga Karbowniczek; Jon Extance; Paul J Rothwell; Ifeayinwa Orefo; John P Tite; Freda K Stevenson; Christian H Ottensmeier; Natalia Savelyeva
Journal:  Cancer Immunol Immunother       Date:  2018-01-12       Impact factor: 6.968

9.  Production of lentiviral vectors using novel, enzymatically produced, linear DNA.

Authors:  Rajvinder Karda; John R Counsell; Kinga Karbowniczek; Lisa J Caproni; John P Tite; Simon N Waddington
Journal:  Gene Ther       Date:  2019-01-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.